Call Now Open
Oxford-Harrington Rare Disease Scholar Award
The Oxford-Harrington Rare Disease Scholar Award advances promising discoveries from academic labs to move them into clinical practice. The award combines funding and expert therapeutics development support to help researchers in the UK, US, or Canada to accelerate preclinical projects towards treatments for patients.
The grant is administered by the Oxford-Harrington Rare Disease Centre (OHC), a partnership between the University of Oxford and Harrington Discovery Institute at University Hospitals in Cleveland, Ohio. Harrington Discovery Institute’s UK granting organization is Fund for Cures UK, Ltd.
Specifically, the award includes:
*Advisors with Harrington’s Therapeutics Development Center have capabilities in biology/biophysiology, commercial and business development, formulation, medicinal chemistry, pharmacology, pre-clinical and clinical planning, and regulatory and translational. The advisors have previously held leadership positions at companies such as Merck, Bristol Myers Squibb, Schering-Plough, Forest Laboratories, GlaxoSmithKline, Johnson & Johnson, AstraZeneca, and Allergan.
Join our emailing list to become a part of our community and receive periodic communications about grant funding opportunities, as well as news and updates.
Past recipients of Harrington awards may submit new and distinct proposals, but may not seek additional support for previously funded projects.
We welcome and encourage multiple proposals from each institution.
Late submissions will not be accepted for any reason, other than issues with the Harrington Discovery Institute’s submission system. Proposals received after the deadline will not be reviewed.
The Oxford-Harrington Rare Disease Scholar Award seeks novel approaches to treat rare diseases. Proposals of interest include discoveries demonstrating rigorous science, innovation, and potential for clinical impact. Projects with novel, validated targets are of particular interest.
The current focus areas of the OHC are neurological disorders, developmental disorders, and rare cancers, but we welcome applications directed to other rare, genetic indications with a high unmet need. Any therapeutic modality will be considered.
Key considerations also include:
Emphasis of Call